These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30157531)

  • 21. Dietary tartary buckwheat intake attenuates insulin resistance and improves lipid profiles in patients with type 2 diabetes: a randomized controlled trial.
    Qiu J; Liu Y; Yue Y; Qin Y; Li Z
    Nutr Res; 2016 Dec; 36(12):1392-1401. PubMed ID: 27919453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vegetarian diet improves insulin resistance and oxidative stress markers more than conventional diet in subjects with Type 2 diabetes.
    Kahleova H; Matoulek M; Malinska H; Oliyarnik O; Kazdova L; Neskudla T; Skoch A; Hajek M; Hill M; Kahle M; Pelikanova T
    Diabet Med; 2011 May; 28(5):549-59. PubMed ID: 21480966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy.
    Mori Y; Taniguchi Y; Miyazaki S; Yokoyama J; Utsunomiya K
    Diabetes Technol Ther; 2013 Mar; 15(3):237-40. PubMed ID: 23402316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
    Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK
    Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    Turner RC; Cull CA; Frighi V; Holman RR
    JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Individualized Meal Replacement Therapy Improves Clinically Relevant Long-Term Glycemic Control in Poorly Controlled Type 2 Diabetes Patients.
    Kempf K; Röhling M; Niedermeier K; Gärtner B; Martin S
    Nutrients; 2018 Aug; 10(8):. PubMed ID: 30081574
    [No Abstract]   [Full Text] [Related]  

  • 27. Beneficial effects of green cardamom on serum SIRT1, glycemic indices and triglyceride levels in patients with type 2 diabetes mellitus: a randomized double-blind placebo controlled clinical trial.
    Aghasi M; Koohdani F; Qorbani M; Nasli-Esfahani E; Ghazi-Zahedi S; Khoshamal H; Keshavarz A; Sotoudeh G
    J Sci Food Agric; 2019 Jun; 99(8):3933-3940. PubMed ID: 30701554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Effect of Dietary Glycaemic Index on Glycaemia in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ojo O; Ojo OO; Adebowale F; Wang XH
    Nutrients; 2018 Mar; 10(3):. PubMed ID: 29562676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin-A Randomized, Crossover, Active-Controlled Study.
    Denney WS; Denham DS; Riggs MR; Amin NB
    Clin Pharmacol Drug Dev; 2016 Nov; 5(6):517-527. PubMed ID: 27870481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Diabetes-Specific Nutritional Formulas versus Oatmeal on Postprandial Glucose, Insulin, GLP-1 and Postprandial Lipidemia.
    Mottalib A; Mohd-Yusof BN; Shehabeldin M; Pober DM; Mitri J; Hamdy O
    Nutrients; 2016 Jul; 8(7):. PubMed ID: 27455318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of efficacy and safety of once- versus twice-daily insulin detemir added on to oral antidiabetics in insulin-naive type 2 diabetes patients: 24-week, crossover, treat to target trial in a single center.
    Cander S; Dizdar OS; Oz Gul O; Guclu M; Unal OK; Tuncel E; Erturk E; Imamoglu S; Ersoy C
    Prim Care Diabetes; 2014 Oct; 8(3):256-64. PubMed ID: 24522170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.
    Testa MA; Gill J; Su M; Turner RR; Blonde L; Simonson DC
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3504-14. PubMed ID: 22851487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical characteristics of type 2 diabetic patients on basal insulin therapy with adequate fasting glucose control who do not achieve HbA1c targets.
    Mata-Cases M; Mauricio D; Franch-Nadal J
    J Diabetes; 2017 Jan; 9(1):34-44. PubMed ID: 26749415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of chromium-enriched yeast on fasting plasma glucose, glycated haemoglobin and serum lipid levels in patients with type 2 diabetes mellitus treated with insulin.
    Racek J; Sindberg CD; Moesgaard S; Mainz J; Fabry J; Müller L; Rácová K
    Biol Trace Elem Res; 2013 Oct; 155(1):1-4. PubMed ID: 23921483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study.
    King AB
    Diabetes Obes Metab; 2009 Jan; 11(1):69-71. PubMed ID: 19120433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.
    Fonseca VA; Valiquett TR; Huang SM; Ghazzi MN; Whitcomb RW
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3169-76. PubMed ID: 9745421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuous Subcutaneous Insulin Infusion (CSII) Pumps for Type 1 and Type 2 Adult Diabetic Populations: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(20):1-58. PubMed ID: 23074525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of low-carbohydrate/high-monounsaturated fatty acid liquid diets on diurnal glucose variability and insulin dose in type 2 diabetes patients on tube feeding who require insulin therapy.
    Mori Y; Ohta T; Yokoyama J; Utsunomiya K
    Diabetes Technol Ther; 2013 Sep; 15(9):762-7. PubMed ID: 23931715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycemic Variability and Insulin Needs in Patients with Type 1 Diabetes Mellitus Supplemented with Vitamin D: A Pilot Study Using Continuous Glucose Monitoring System.
    Felício KM; de Souza ACCB; Neto JFA; de Melo FTC; Carvalho CT; Arbage TP; de Rider Brito HA; Peixoto AS; de Oliveira AF; de Souza Resende F; Reis SS; Motta AR; da Costa Miranda H; Janau LC; Yamada ES; Felicio JS
    Curr Diabetes Rev; 2018; 14(4):395-403. PubMed ID: 28618984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.